RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.

Published

Journal Article

BACKGROUND: Prostate adenocarcinoma (AdPC) progression to treatment-induced neuroendocrine prostate cancer (t-NEPC) is associated with poor patient survival. While AdPC and t-NEPC share similar genomes, they possess distinct transcriptomes, suggesting that RNA splicing and epigenetic mechanisms may regulate t-NEPC development. OBJECTIVE: To characterize the role of alternative RNA splicing of the histone demethylase BHC80 during t-NEPC progression. DESIGN, SETTING, AND PARTICIPANTS: The expression of BHC80 splice variants (BHC80-1 and BHC80-2) were compared between AdPC and t-NEPC patient tumors. Regulatory mechanisms of RNA splicing of the BHC80 gene were studied, and the signal pathways mediated by BHC80 splice variants were investigated in t-NEPC cell and xenograft models. RESULTS: Global transcriptome analyses identified that the BHC80-2 variant is highly expressed in t-NEPC. Compared with the known histone demethylation activities of the BHC80 gene, we discovered a novel nonepigenetic action of BHC80-2, whereby BHC80-2 is localized in the cytoplasm to trigger the MyD88-p38-TTP pathway, which results in increased RNA stability of multiple tumor-promoting cytokines. While BHC80-2 does not induce neuroendocrine differentiation of cancer cells, it stimulates cell proliferation and tumor progression independent of androgen receptor signaling. Blockade of BHC80-2-regulated MyD88 signaling suppresses growth of several t-NEPC cell spheroid and xenograft models. CONCLUSIONS: Gain of function of BHC80-2 through alternative RNA splicing activates immune responses of cancer cells to promote t-NEPC development. PATIENT SUMMARY: The main obstacle to develop effective therapies for patients with t-NEPC is the lack of understanding on how t-NEPC is developed. Our study not only identifies a previously unknown BHC80-2-MyD88 signaling pathway that plays an important role during t-NEPC development, but also provides a proof of principle that targeting this signal pathway may offer an avenue to treat t-NEPC.

Full Text

Duke Authors

Cited Authors

  • Li, Y; Xie, N; Chen, R; Lee, AR; Lovnicki, J; Morrison, EA; Fazli, L; Zhang, Q; Musselman, CA; Wang, Y; Huang, J; Gleave, ME; Collins, C; Dong, X

Published Date

  • August 2019

Published In

Volume / Issue

  • 76 / 2

Start / End Page

  • 157 - 166

PubMed ID

  • 30910347

Pubmed Central ID

  • 30910347

Electronic International Standard Serial Number (EISSN)

  • 1873-7560

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2019.03.011

Language

  • eng

Conference Location

  • Switzerland